New Research Projects

H2020 funding to study metabolic effects of endocrine disruptors

The EDCMET project coordinated by the University of Eastern Finland has secured Horizon 2020 funding to study the molecular mechanisms behind the adverse metabolic effects of endocrine disruptors and to develop testing methods for these studies.

The objective of the EDCMET project is to develop validated in silico, in vitro and in vivo methods assessing detailed biological changes and adverse metabolic effects of EDs, with a focus on energy and fat metabolism and nuclear receptors regulating these processes. EDCMET utilizes a wide variety of methodologies, ranging from computational methods, cell culture systems and up-to-date animal models, to epidemiological data, to reliably associate the exposure to chemicals to ED-related metabolic effects.

EDCMET brings together experts, researchers and companies from several scientific fields and eight European countries. The project is running from 1.1.2019–31.12.2023 and is coordinated by Professor Anna-Liisa Levonen from A.I. Virtanen Institute. At the School of Pharmacy, research groups led by Professor Paavo Honkakoski and Associate Professor Jaana Rysä, as well as the molecular modeling group of Professor Antti Poso at University of Tübingen, are participating in the project.

Further information:

Professor Paavo Honkakoski, paavo.honkakoski(at), p. +358403552490

Associate Professor Jaana Rysä, jaana.rysa(at), p. +358503164105

Professor Antti Poso, antti.poso(at), p. +358403552462


NordForsk awarded grant for patient oriented pharmaceutical products

NordForsk, a facilitator and provider of funding for Nordic research cooperation, has awarded four million euros to a research consortium seeking to develop patient oriented pharmaceutical products. The School of Pharmacy at the University of Eastern Finland is one of the ten consortium partners. The six-year Nordic POP project is coordinated by the University of Copenhagen. The other consortium partners include the University of Helsinki, Åbo Akademi University, the University of Iceland, the University of Oslo, Uppsala University, the University of Southern Denmark, the Arctic University of Norway, and the Chalmers University of Technology.

Constituting part of NordForsk’s Nordic University Hub programme, the Nordic POP (Patient Oriented Products) project seeks to develop innovative patient oriented products and to introduce a paradigm shift in the design and manufacturing of pharmaceutical products, as well as in their performance assessment.  This will enable increasingly personalised treatment plans. 

The project will strengthen multidisciplinary collaboration in pharmaceutical research by promoting researcher mobility within the consortium. The project also seeks to serve as a foundation for new start-up companies, and to disseminate its innovations to Nordic pharmaceutical companies.

For further information, please contact:

Professor Jarkko Ketolainen, University of Eastern Finland, School of Pharmacy, jarkko.ketolainen (a), tel. +358403552486

1.5 Meuros for Biohybrid Technologies for Modern Biomedicine

The project will lanch a new laboratory project to the Institute of Chemistry, St. Petersburg State University to study new biomaterials for ocular drug delivery and for cellular engineering. The project aims to improve drug delivery by prolonging duration of action and targeting drugs to their intracellular sites of action. The grant includes part time position for the leading scientist Professor Arto Urtti at Institute of Chemistry, St. Petersburg State University.

The project timeline is 1.1.2018-31.12.2020.

For further information, please contact

Professor Arto Urtti, arto.urtti(at), tel +358405402279

Three-year grant from Academy of Finland for biogenic amines research

300 000 euros of funding was granted for Professor Jouko Vepsäläinen from the University of Eastern Finland School of Pharmacy.

Addressing the Changing Arctic climate, changing diseases theme, the Biogenic amines in the health challenge caused by the changing Arctic climate (ABIOHEALTH) project focuses on the role and significance of polyamines in environmental and disease-related stress reactions that are caused by climate change. The project seeks to develop novel experimental drugs for pathogenic microorganisms and diseases that will become increasingly prevalent in the Arctic due to climate change.

For further information, please contact:

Professor Jouko Vepsäläinen, jouko.vepsalainen(at), tel+358403553256

Eu grant for Integrated Training in Dry Eye Disease Drug Development (IT-DED3)

The European network for Integrated Training in Dry Disease Drug Development aims to deliver multidisciplinary and entrepreneurial researchers trained to develop new therapies for patients suffering from dry eye diseases (DED). DED is a chronic, multifactorial disease of the ocular surface and is a major and increasing healthcare problem due to its high prevalence and ecenomic burden because of the ageining population and frequent computer/tablet/smartphone usage. IT-DED3 integrates expertise in medicinal chemistry , process chemistry, ocular drug delivery and formulation , ocular biology, in vitro and in vivo evaluation and imaging, biomarker research and clinical ophthalmology.

 Information about IT-DED3;

The project timeline is 1.1.2018 - 31.12.2021

For further information, please contact

Professor Arto Urtti, arto.urtti(at), tel +358405402279

Academy of Finland  grant over 440 000 euros  for melasomes in drug targeting to the retina

The project investigates drug binding to melanin and its effect on drug pharmacokinetics in the retina by using cell-based and animal studies and advanced computer modeling. The ultimate aim of the project is to generate models and scaffolds to advance the development of retina-targeting drugs with long-lasting effects.

The project timeline is between 1.9.2017-31.8.2021.

For further information, please contact

Professor Arto Urtti, arto.urtti(at), tel +358405402279